



## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and	
Name of listed issuer:	Ryman Healthcare Limited
Date this disclosure made:	02-Jul-20
Date of last disclosure:	2 December 2019 (as part of SPH notice)

#### Director or senior manager giving disclosure

Full name(s):	Warren James Bell
Name of listed issuer:	Ryman Healthcare Limited
Name of related body corporate (if applicable):	NA
Position held in listed issuer:	Director

#### Summary of acquisition or disposal of relevant interest (excluding specified derivatives)

Class of affected quoted financial products:	Ordinary shares
Nature of the affected relevant interest(s):	Warren is a director of Hickman Family Trustees Limited (HFTL) (which is the registered holder of the shares as trustee of the Hickman Family Trust) and has control over the exercise of a right to vote attached to the shares as the sole independent director of HFTL (alongside the other directors of HFTL)
For that relevant interest-	
Number held in class before acquisition or disposal:	35,000,000
Number held in class after acquisition or disposal:	33,000,000
Current registered holder(s):	Hickman Family Trustees Limited
Registered holder(s) once transfers are registered:	Hickman Family Trustees Limited

#### Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

Type of affected derivative:	N/A
Class of underlying financial products:	N/A

#### Details of affected derivative-

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically settled:	N/A
Maturity date of the derivative (if any):	N/A
Expiry date of the derivative(if any):	N/A
The price specified in the terms of the derivative (if any):	N/A
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:	N/A
For that derivative,-	
Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:	N/A

#### Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:	4
---	---

**Details of transactions requiring disclosure-**

Date of transaction:
Nature of transaction:
Name of any other party or parties to the transaction (if known):
<p>The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:</p>
<p>Number of financial products to which the transaction related:</p> <p><i>If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—</i></p>
Whether relevant interests were acquired or disposed of during a closed period:
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period:
Date of the prior written clearance (if any):

(1) 26 June 2020  
(2) 30 June 2020  
(3) 1 July 2020  
(4) 2 July 2020

On market sales

Unknown (on market)

Total consideration of \$26,048,269.70 (at an average of \$13.0241 per share), made up as follows:

(1) \$7,800,000.00 (being \$13.0000 per share)  
(2) \$5,286,546.00 (being \$13.0532 per share)  
(3) \$8,512,914.48 (being \$13.0381 per share)  
(4) \$4,448,809.20 (being \$13.0054 per share)

A total of 2,000,000 ordinary shares, made up as follows:

(1) 600,000 ordinary shares  
(2) 405,000 ordinary shares  
(3) 652,926 ordinary shares  
(4) 342,074 ordinary shares

All directors transactions require approval

Prior written clearance from Ryman Healthcare was obtained.

24 June 2020

**Summary of other relevant interests after acquisition or disposal:**

Class of quoted financial products:
Nature of relevant interest:
<i>For that relevant interest, -</i>
Number held in class:
Current registered holder(s):
<i>For a derivative relevant interest, -</i>
Type of derivative:

Ordinary shares

Registered holder and beneficial owner

1500

Warren James Bell

NA

**Details of derivative,-**

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):
A statement as to whether the derivative is cash settled or physically settled:
Maturity date of the derivative (if any):
Expiry date of the derivative (if any):
The price's specified terms (if any):
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:
<i>For that derivative relevant interest, -</i>
Parties to the derivative:
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

NA

NA

NA

NA

NA

NA

NA

NA

**Certification**

I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made.

Signature of director or officer:


Date of signature:

or

Signature of person authorised to sign on behalf of director or officer:

Date of signature:

Name and title of authorised person:



Warren James Bell

02/07/2020
